Stem Cell Market Research Reports & Industry Analysis
Cells must meet very specific criteria in order to be termed stem cells. They must: produce copies themselves; proliferate at a rapid rate; and display certain proteins on their surface that indicate a capacity to differentiate into other tissues, such as bone and cartilage. A stem cell line is a group of cells that all descend from a single original stem cell. Symmetric division gives rise to two identical daughter cells both endowed with stem cell properties. Asymmetric division produces only one stem cell and a progenitor cell with limited self-renewal potential.
Stem Cell Industry Research & Market Reports
-
Stem Cell Banking
... at a CAGR of 7.5% over the analysis period 2024-2030. Placental and Cord Blood Stem Cells, one of the segments analyzed in the report, is expected to record a 8.2% CAGR and reach US$10.5 Billion ... Read More
-
Induced Pluripotent Stem Cell (iPSC)
... Billion by 2030, growing at a CAGR of 7.0% over the analysis period 2024-2030. Vascular Cells, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$1.1 Billion ... Read More
-
Human Organoids
... CAGR of 15.4% over the analysis period 2024-2030. Kidney, one of the segments analyzed in the report, is expected to record a 16.2% CAGR and reach US$1.6 Billion by the end of the analysis period. ... Read More
-
Primary Immunodeficiency Therapeutics
... at a CAGR of 6.4% over the analysis period 2024-2030. Antibody Deficiency, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$8.5 Billion by the end of ... Read More
-
Cord Blood Banking Services
... 2030, growing at a CAGR of 10.1% over the analysis period 2024-2030. Private, one of the segments analyzed in the report, is expected to record a 10.6% CAGR and reach US$79.3 Billion by the end ... Read More
-
Stem Cell Assays
... at a CAGR of 17.9% over the analysis period 2024-2030. Instruments, one of the segments analyzed in the report, is expected to record a 18.4% CAGR and reach US$6.1 Billion by the end of the ... Read More
-
Cell Viability Assays
... at a CAGR of 7.1% over the analysis period 2024-2030. Consumables, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$5.3 Billion by the end of the ... Read More
-
Canine Stem Cell Therapy
... 2030, growing at a CAGR of 3.4% over the analysis period 2024-2030. Allogeneic Stem Cells, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$174.8 Million by ... Read More
-
Stem Cell Services
... at a CAGR of 9.8% over the analysis period 2024-2030. The U.S. Market is Estimated at US$8.3 Billion While China is Forecast to Grow at 9.0% CAGR The Stem Cell Services market in the U.S. ... Read More
-
Exosomes
... 14.6% over the analysis period 2024-2030. Cancer, one of the segments analyzed in the report, is expected to record a 16.5% CAGR and reach US$921.6 Million by the end of the analysis period. Growth in ... Read More
-
Hematopoietic Stem Cell Transplantation
... 2030, growing at a CAGR of 7.5% over the analysis period 2024-2030. Allogenic Transplant Therapy Type, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$2.6 Billion ... Read More
-
Cancer Stem Cells
... at a CAGR of 8.5% over the analysis period 2024-2030. Stem Cell-based Cancer Therapy, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$1.3 Billion by the ... Read More
-
GMP Cell Banking Services
... 2030, growing at a CAGR of 15.0% over the analysis period 2024-2030. Biopharmaceutical Companies, one of the segments analyzed in the report, is expected to record a 14.6% CAGR and reach US$1.5 Billion by the ... Read More
-
Cell Banking Outsourcing
... at a CAGR of 16.1% over the analysis period 2024-2030. Master Cell Banking, one of the segments analyzed in the report, is expected to record a 18.5% CAGR and reach US$19.7 Billion by the end ... Read More
-
Mesenchymal Stem Cells (MSC)
... 2030, growing at a CAGR of 12.2% over the analysis period 2024-2030. Bone Marrow, one of the segments analyzed in the report, is expected to record a 13.2% CAGR and reach US$3.4 Billion by the ... Read More
-
ADME-Toxicology Testing
... CAGR of 11.2% over the analysis period 2024-2030. Cell Culture, one of the segments analyzed in the report, is expected to record a 13.2% CAGR and reach US$9.6 Billion by the end of the analysis ... Read More
-
Stem Cells
... CAGR of 7.4% over the analysis period 2024-2030. Adult Stem Cells, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$17.8 Billion by the end of the ... Read More
-
Stem Cell Manufacturing
... at a CAGR of 7.8% over the analysis period 2024-2030. Culture Media, one of the segments analyzed in the report, is expected to record a 7.6% CAGR and reach US$9.2 Billion by the end of ... Read More
-
Amniotic Products
... CAGR of 8.1% over the analysis period 2024-2030. Amniotic Membranes, one of the segments analyzed in the report, is expected to record a 8.6% CAGR and reach US$1.2 Billion by the end of the analysis ... Read More
-
Viral Inactivation
... CAGR of 11.6% over the analysis period 2024-2030. Kits & Reagents, one of the segments analyzed in the report, is expected to record a 11.5% CAGR and reach US$865.8 Million by the end of the ... Read More
-
Rat Model
... CAGR of 7.1% over the analysis period 2024-2030. Inbred, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$901.6 Million by the end of the analysis period. ... Read More
-
Primary Cells
... CAGR of 7.1% over the analysis period 2024-2030. Human Primary Cells, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$1.4 Billion by the end of the ... Read More
-
Live Cell Imaging
... at a CAGR of 7.4% over the analysis period 2024-2030. Cell Biology, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$1.8 Billion by the end of ... Read More
-
Cell And Gene Therapy CDMO Market Size, Share & Trends Analysis Report By Phase (Pre-clinical, Clinical), By Product Type (Gene Therapy, Gene-Modified Cell Therapy, Cell Therapy), By Indication (Oncology, Infectious Diseases), By Region, And Segment- Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
... the forecast period from 2024 to 2033. Key Takeaways: North America accounts for the largest share of 40.18% in 2023. Asia Pacific, on the other hand, is anticipated to register a lucrative CAGR of 29.1% ... Read More
-
Cell And Gene Therapy Manufacturing Market Size, Share & Trends Analysis Report By Therapy Type, By Scale (R&D), By Mode, By Workflow (Vector Production, Cell Banking), By Region, And Segment- Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
... the forecast period from 2024 to 2033. Key Takeaways: North America accounted for the highest revenue share of 48.32% in 2023. Asia Pacific is anticipated to be a growing market for cell and gene therapy ... Read More
Research Assistance
